Celera (NASDAQ:CRA) today announced the appointment of Christopher Hall as Chief Business Officer of Berkeley HeartLab (BHL), effective immediately. Mr. Hall succeeds Frank Ruderman, the former Chairman and CEO of BHL, who is leaving the company to pursue other interests following the successful integration of BHL into Celera. Mr. Ruderman will consult for Celera during a transition period. Mr. Hall will report to Kathy Ordonez, Celera’s Chief Executive Officer.

Mr. Hall has held several executive and senior positions at BHL over the last 6 years, including serving as Chief Clinical Operations Officer since 2005. In this capacity, Mr. Hall led more than 100 people in the business’s disease management unit where he was responsible for program development, resource deployment, business development, and marketing. Key accomplishments under Mr. Hall’s leadership include the successful implementation of 4myheart Centers, the 4myheart Tele-connect program and 4myheart.com website. Before that, Chris served as Vice President of Marketing where he was instrumental in repositioning BHL from a specialty laboratory for advanced lipid blood tests to a cardiovascular disease management company. Prior to joining BHL, he held management and financial positions with Asimba, Inc., and Symmetrix.

Mr. Hall holds a Bachelor of Arts degree from DePauw University, Greencastle, IN, and an M.B.A. from Harvard University, Boston, MA.

“Chris has contributed significantly to the growth at Berkeley HeartLab over the past six years,” said Kathy Ordonez, Chief Executive Officer of Celera. “His creativity and understanding of disease management will be pivotal in helping us drive the business forward, to the benefit of both Berkeley HeartLab and Celera.”